Want to see JP:7096 full AI Analyst Report?
StemCell Institute (7096) AI Stock Analysis
StemCell Institute
(TSE/TYO:7096)
The score is driven primarily by weakened financial quality in 2026—sharp profitability compression and materially negative free cash flow—despite steady revenue growth and a generally healthy, low-leverage balance sheet. Technical indicators are moderately supportive in the near term, but the high P/E (~52) keeps the valuation component weak and raises execution-risk sensitivity.
StemCell Institute (7096) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 7.06B
- Dividend Yield
- ―
- Average Volume (3M)
- 4,208
- Price to Earnings (P/E)
- 48.1
- Beta (1Y)
- 0.46
- Revenue Growth
- 4.85%
- EPS Growth
- -40.57%
- Country
- Japan
- Employees
- 117
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
StemCell Institute Business Overview & Revenue Model
Company Description
StemCell Institute Inc. provides specialized stem cell banking services throughout Japan. In addition to its core preservation activities, the company is deeply involved in the research and development of medical therapies that utilize stem cells, an...
How the Company Makes Money
null
StemCell Institute Financial Statement Overview
Summary
Mixed fundamentals. Revenue growth has been steady, and gross margin remains solid (~61% in 2026), but profitability weakened sharply in 2026 (net margin fell to ~5.5% from ~14.4% in 2025). The balance sheet is generally healthy with low-to-modest leverage (debt-to-equity ~0.18), yet cash flow is a major concern: operating cash flow dropped and free cash flow swung to a large deficit in 2026.
Income Statement
64PositiveBalance Sheet
72PositiveCash Flow
34Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.81B | 2.81B | 2.68B | 2.48B | 2.09B | 1.78B |
| Gross Profit | 1.71B | 1.71B | 1.69B | 1.58B | 1.34B | 1.11B |
| EBITDA | 368.87M | 379.99M | 695.19M | 534.00M | 402.49M | 309.47M |
| Net Income | 153.86M | 155.92M | 385.80M | 310.98M | 198.03M | 133.73M |
Balance Sheet | ||||||
| Total Assets | 8.12B | 8.12B | 7.52B | 6.59B | 5.83B | 5.23B |
| Cash, Cash Equivalents and Short-Term Investments | 2.83B | 2.83B | 3.20B | 2.85B | 3.32B | 3.51B |
| Total Debt | 473.81M | 473.81M | 518.96M | 10.78M | 5.89M | 0 |
| Total Liabilities | 5.05B | 5.05B | 4.89B | 3.90B | 3.53B | 3.13B |
| Stockholders Equity | 2.68B | 2.68B | 2.63B | 2.69B | 2.30B | 2.10B |
Cash Flow | ||||||
| Free Cash Flow | 0 | -335.78M | -10.11M | 132.97M | 39.77M | 264.81M |
| Operating Cash Flow | 0 | 73.51M | 467.69M | 334.63M | 99.67M | 469.29M |
| Investing Cash Flow | 0 | -337.92M | -259.08M | -811.77M | -285.10M | 404.17M |
| Financing Cash Flow | 0 | -175.09M | 146.70M | -1.33M | -869.00K | 644.37M |
StemCell Institute Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7096, the sentiment is Negative. The current price of 701.00 is below the 20-day moving average (MA) of 727.10, below the 50-day MA of 743.32, and below the 200-day MA of 760.23, indicating a bearish trend. The MACD of -9.74 indicates Positive momentum. The RSI at 29.46 is Positive, neither overbought nor oversold. The STOCH value of 27.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:7096.
StemCell Institute Peers Comparison
Overall Rating
- JP:709656Neutral
JP:459348Neutral
JP:497842Neutral
JP:777442Neutral
JP:459940Underperform
JP:777626Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| JP:7096 | 56Neutral | JPY 7.18B | 48.11 | ― | ― | 4.85% | -40.57% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| JP:4593 | 48Neutral | JPY 37.00B | 55.04 | ― | ― | -47.32% | ― |
| JP:4978 | 42Neutral | JPY 13.03B | -26.58 | ― | ― | -18.71% | -246.54% |
| JP:7774 | 42Neutral | JPY 25.54B | -58.02 | ― | ― | 3.43% | -53.59% |
| JP:4599 | 40Underperform | JPY 8.71B | -4.68 | ― | ― | ― | 4.85% |
| JP:7776 | 26Underperform | JPY 7.43B | -6.49 | ― | ― | -56.16% | 3.12% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:7096 | StemCell Institute | 701.00 | -109.00 | -13.46% | |
| JP:4593 | Healios KK | 273.00 | -221.00 | -44.74% | |
| JP:4599 | StemRIM Inc. | 139.00 | -134.00 | -49.08% | |
| JP:4978 | ReproCELL Inc. | 122.00 | -51.00 | -29.48% | |
| JP:7774 | Japan Tissue Engineering Co., Ltd. | 629.00 | 153.00 | 32.14% | |
| JP:7776 | CellSeed Inc. | 188.00 | -249.00 | -56.98% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 17, 2026